Help at Home acquired by The Vistria Group / Centerbridge Partners

UNITED STATES Health Providers / Healthcare Facilities / Nursing Homes EV $1–10bn

Context

Vistria and Centerbridge Partners jointly acquired Help at Home from Wellspring Capital Management, which had owned the business for approximately five years. The transaction represents the final platform investment of Vistria Fund II and simultaneously the first investment of Vistria Fund III, reflecting the deal's significance within Vistria's fund lifecycle. Vistria and Centerbridge will hold equal board representation at Help at Home. The investment is consistent with Vistria's thematic focus on the structural shift in US healthcare delivery toward home and community-based settings, and follows their prior joint investment in Civitas in 2019

Help at Home, which reported an EBITDA margin of [members only] in 2020, is valued in this transaction at an EV/EBITDA multiple of 10x–18x, standing directly in line with the average observed in the Healthcare & Pharma sector (14.6x in 2020).

-> Deep-dive in Healthcare & Pharma market trends

Target

Help at Home is a leading US provider of home care and community-based services, founded in 1975 and headquartered in Chicago, Illinois. The company provides a broad range of medical and non-medical in-home care services to seniors and persons with disabilities across 13 states — Alabama, Georgia, Illinois, Indiana, Iowa, Kansas, Kentucky, Michigan, Mississippi, Missouri, Pennsylvania, South Carolina, and Tennessee — through a network of more than 155 locations caring for over 60,000 clients. Help at Home's model is centred on enabling elderly and disabled individuals to continue living independently in their homes and communities, rather than in institutionalised care settings.

Ent. Value

$1–10bn

Equity Value

[members only]

Multiples

EV / Revenue

[members only]

EV / EBITDA

10x–18x

EV / EBIT

[members only]

Historical Financials (USD)

Year

Rev

EBITDA

EBIT

2020

2019

Similar deals in Health Providers

Similar deals in Health Providers
Date	Acquirer	Target	Country	Sector
11/2020	DWS GROUP	MEDIPASS	ITALY	Radiology
11/2020	APHEON	VIDACURA	GERMANY	Nursing Homes
10/2020	INFRATIL	QSCAN GROUP	AUSTRALIA	Radiology
10/2020	KKR / TETHYS INVEST / ARDIAN / CNP ASSURANCES / MERIEUX EQUITY PARTNERS	ELSAN	FRANCE	Clinics / Hospitals
09/2020	EQT PARTNERS	COLISÉE	FRANCE	Nursing Homes
09/2020	VAM INVESTMENTS	DEMENEGO	ITALY	Ophthalmology
07/2020	ORPEA	BRINDLEY HEALTHCARE	IRELAND	Nursing Homes
07/2020	BIOGROUP	LABORIZON	FRANCE	Labs (Biology)
06/2020	ASKLEPIOS KLINIKEN	RHÖN-KLINIKUM	GERMANY	Clinics / Hospitals
03/2020	ORPEA	TLC GROUP	IRELAND	Nursing Homes

REFERENCES

Valuation range: EV $1–10bn

EBITDA range: $100–200M

EV/EBITDA range: 10x - 18x

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Help at Home by The Vistria Group / Centerbridge Partners are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Target: help at home

Acquirer: centerbridge partners / the vistria group

FAQ

What transaction does this page cover?

This page covers the acquisition of 100% of Help at Home, an American company specialised in Healthcare Facilities, by The Vistria Group and Centerbridge Partners in 2020.

How was the acquisition of Help at Home by The Vistria Group valued, and what multiples were paid?

mynth displays the transaction’s enterprise value within the $1–10bn band and its EV/EBITDA multiple within the 10x - 18x range. Exact figures are available to members.

What was Help at Home’s EBITDA at the time of the deal?

At the time of the transaction, Help at Home’s EBITDA was estimated within the $100–200M bracket (FY 2020). Detailed financial figures are available to members.

How does the valuation of Help at Home compare to benchmarks in the Healthcare & Pharma sector?

With an estimated multiple range of 10x - 18x, the transaction stands directly in line with historical averages for the Healthcare & Pharma sector (14.6x in 2020).

What sources support the information on this transaction?

Data on this transaction was compiled from the official corporate announcement published by the parties, combined with independent reporting from specialized financial and M&A publications.

What is mynth?

mynth is the first free M&A database dedicated to Small & Mid-Cap transactions. We centralize Enterprise Values, revenue multiples, EBITDA multiples and transaction financials that are typically locked behind five-figure subscriptions on platforms like Capital IQ or Mergermarket. On mynth, searching and browsing deals is completely free. Our mission is simple: make professional-grade valuation intelligence accessible to every M&A advisor, independent consultant, Private Equity professional and student, without the burden of expensive annual licenses.